ZLZhelong Li

Zhelong Li

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Zhelong Li has a total of 29 co-authors. Here are the top co-authors by number of shared publications:

  • Guodong Yang

    Department of Biochemistry and Molecular Biology, the Fourth Military Medical University, Xi'an, China

    3 shared publications
  • Lijun Yuan

    Department of Ultrasound Diagnostics, Tangdu Hospital, Fourth Military Medical University, Xi’an, China

    3 shared publications
  • Mengying Wei

    The State Laboratory of Cancer Biology, Department of Biochemistry and Molecular Biology

    2 shared publications
  • Xiaotong Gao

    Department of Hematology, Tangdu Hospital, Fourth Military Medical University, Xi’an, 710038, Shaanxi, China

    2 shared publications
  • Zhuo Wan

    Department of Hematology, Tangdu Hospital, Fourth Military Medical University, Xi’an 710032, Shaanxi, China

    2 shared publications
  • Bingzhang Xu

    Department of Ultrasound Diagnostics, Tangdu Hospital, Fourth Military Medical University, Xi'an, China

    1 shared publication

Latest Publications

  • Synergistic “targeting and blockade” strategy via engineered exosomes and clinical ultrasound contrast agent for hepatocyte-targeted mRNA delivery

    by Zhelong Li, Bo Zhang, Chunmao Liu, Wei Wang, Guoping Li, Bingzhang Xu, Feng Liu, Xinyu Li, Chuan Dong, Ping Zhao, et al.

  • “All-in-One” Exosome Engineering Strategy for Effective Therapy of Familial Hypercholesterolemia

    by Ruiyan Mei, Zhuo Wan, Zhelong Li, Mengying Wei, Weiwei Qin, Lijun Yuan, Li Liu, Guodong Yang

    Exosomes serve as a promising therapeutic nanoplatform. However, the exosomes produced by donor cells are a heterogeneous group, with only a small portion having high therapeutic efficacy. Specific isolation of the subpopulation with high efficacy is important for lowering the dose and minimizing toxicity. In this study, we loaded target mRNA and displayed specific Flag in engineered exosomes simultaneously. Briefly, the donor cells were transfected with plasmid expressing a fusion protein Flag-TCS-PTGFRN-CTSL-MCP, namely, exosome sorter. During biogenesis, the RNA-binding motif MCP can specifically bind with MS2-containing RNA and sort the target RNA into the lumen of exosomes. Anti-Flag magnetic beads can capture and thus purify the engineered exosomes via recognition of the Flag on the surface of exosomes. After purification, the Flag could be cleaved by thrombin treatment while MCP can be separated from the fusion protein by CTSL autocleavage upon exosome acidification, minimizing the side effects and augmenting the therapeutic effects. By the proof-of-concept experiment, the exosome sorter-based "all-in-one" strategy was confirmed effective in both the encapsulation of therapeutic mRNA (Ldlr-MS2) into exosomes and the subsequent purification. The purified Ldlr-MS2-containing exosomes had much higher efficacy in alleviating atherosclerosis, in comparison with the bulk exosomes, confirming the advantage of the proposed "all-in-one" strategy.


  • Visceral Adipose Tissue Derived Exosomes Exacerbate Colitis Severity via Pro-inflammatory MiRNAs in High Fat Diet Fed Mice

    by Mengying Wei, Xiaotong Gao, Lijun Liu, Zhelong Li, Zhuo Wan, Yan Dong, Xutao Chen, Yu Niu, Jian Zhang, Guodong Yang

    A pioneering epidemic study has revealed a strong association between obesity and the risk of colitis. In this study, a high fat diet was found to significantly aggravate colitis induced by dextran sulfate sodium (DSS). Meanwhile, a high fat diet changed the miRNA profile of the visceral adipose exosomes, switching the exosomes from anti-inflammatory to a pro-inflammatory phenotype. Strikingly, these inflammatory exosomes efficiently circulated into the lamina propria of the intestine, while these exosomes predisposed the intestine to inflammation via promoting macrophage M1 polarization. Mechanistically, the exosomes promoted M1 differentiation at least partially via transferring pro-inflammatory miRNAs, such as miR-155. Moreover, exosome-mediated miR-155 inhibitor delivery significantly prevented DSS-induced colitis. Together, the study has revealed an exosomal pathway of how obesity aggravates colitis and proposes an exosome-based intervention strategy for colitis management.


  • In Vitro and in Vivo RNA Inhibition by CD9-HuR Functionalized Exosomes Encapsulated with miRNA or CRISPR/dCas9

    by Zhelong Li, Xueying Zhou, Mengying Wei, Xiaotong Gao, Lianbi Zhao, Ruijing Shi, Wenqi Sun, Yunyou Duan, Guodong Yang, Lijun Yuan

    In vitro and in vivo delivery of RNAs of interest holds promise for gene therapy. Recently, exosomes are considered as the rational vehicle for RNA delivery, especially miRNA and/or siRNA, while the loading efficiency is limited. In this study, we engineered the exosomes for RNA loading by constructing a fusion protein, in which the exosomal membrane protein CD9 was fused with RNA binding protein, while the RNAs of interest either natively harbors or is engineered to have the elements for the binding. By proof-of-principle experiments, we here fused CD9 with HuR, an RNA binding protein interacts with miR-155 with a relatively high affinity. In the exosome packaging cells, the fused CD9-HuR successfully enriches miR-155 into exosomes when miR-155 was excessively expressed. Moreover, miR-155 encapsulated in the exosomes in turn could be efficiently delivered into the recipient cells and recognizes the endogenous targets. In addition, we also revealed that the CD9-HuR exosomes could enrich the functional miRNA inhibitor or CRISPR/dCas9 when the RNAs were engineered to have the AU rich elements. Taken together, we here have established a novel strategy for RNA cargo encapsulation into engineered exosome, which in turn functions in the recipient cells.